- Eli Lilly & Co $LLY held 2q2011 earnings conference call 7/21/2011 - click here for transcript link.
- LLY has licensed an antisense drug targeting survivin from Isis Pharma (click for details on ISIS research page). This candidate is currently in multiple phase 2 trials for cancer.
- This drug was not mentioned at all in the conference call or in the accompanying slide deck. Note that the drug (LY2183108) is also NOT listed among pipeline compounds moving into phase 3 in 2011.
- LLY also held an extensive Investor Day presentation and Q&A sessions on 6/30/11 (see info on LLY website). This drug was never mentioned in presentation, slides, or Q&A sessions.
RSS Feed
